Skip to main content

Table 2 MRRa for all-cause, cancer-specific and other-cause death among AML CML and myeloma patients, Sweden 2002–2009

From: The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma – a Swedish population-based study

  AMLb MRR (95 % CI) CMLc MRR (95 % CI) Myeloma MRR (95 % CI)
All-cause death
Comorbid disease
 No 1.00 1.00 1.00
 Yes 1.39 (1.26–1.52) 1.64 (1.34–2.01) 1.40 (1.30–1.50)
No. of comorbid diseases
 0 1.00 1.00 1.00
 1 1.25 (1.12–1.38) 1.41 (1.12–1.77) 1.29 (1.19–1.40)
 2+ 1.78 (1.57–2.02) 2.22 (1.71–2.88) 1.67 (1.51–1.85)
Sex    
 Men 1.00 1.00 1.00
 Women 0.91 (0.84–1.00) 0.83 (0.69–1.02) 0.89 (0.83–0.95)
Education level
 0–9 1.00 1.00 1.00
 10–12 0.98 (0.89–1.09) 1.09 (0.89–1.35) 0.97 (0.89–1.04)
  > 12 0.80 (0.70–0.91) 0.93 (0.70–1.25) 0.83 (0.75–0.92)
Cancer-specific death
Comorbid disease
 No 1.00 1.00 1.00
 Yes 1.27 (1.15–1.40) 1.28 (0.96–1.70) 1.17 (1.08–1.28)
No. of comorbid diseases
 0 1.00 1.00 1.00
 1 1.16 (1.04–1.29) 1.12 (0.81–1.55) 1.12 (1.02–1.23)
 2+ 1.60 (1.39–1.83) 1.66 (1.13–2.44) 1.31 (1.15–1.48)
Sex    
 Men 1.00 1.00 1.00
 Women 0.92 (0.84–1.01) 0.91 (0.70–1.20) 0.91 (0.84–0.99)
Education level
 0–9 1.00 1.00 1.00
 10–12 0.97 (0.87–1.08) 1.19 (0.89–1.58) 0.96 (0.88–1.06)
  > 12 0.80 (0.69–0.91) 0.72 (0.46–1.12) 0.87 (0.78–0.97)
Other-cause death
Comorbid disease
 No 1.00 1.00 1.00
 Yes 2.64 (2.00–3.48) 2.14 (1.60–2.85) 2.22 (1.94–2.55)
No. of comorbid diseases
 0 1.00 1.00 1.00
 1 2.22 (1.64–3.01) 1.80 (1.30–2.49) 1.91 (1.64–2.23)
 2+ 3.86 (2.72–5.47) 2.98 (2.07–4.30) 3.02 (2.53–3.62)
Sex    
 Men 1.00 1.00 1.00
 Women 0.90 (0.69–1.16) 0.76 (0.58–1.01) 0.82 (0.72–0.94)
Education level   
 0–9 1.00 1.00 1.00
 10–12 1.07 (0.79–1.43) 1.00 (0.73–1.36) 0.97 (0.83–1.13)
  > 12 0.85 (0.58–1.25) 1.17 (0.80–1.73) 0.72 (0.58–0.88)
  1. aMRR mortality rate ratios adjusted for age (in 10 year intervals), country of birth, time since diagnosis, calendar year of diagnosis and number of comorbid diseases, sex and education level except when main effects of these factors were estimated, statistically significant results (p<0.05) are in bold. bAML acute myeloid leukemia, cCML chronic myeloid leukemia